Ali Roghanian

List of Publications by Year
in descending order

38 papers	1,993 citations	279798 23 h-index	414414 32 g-index
40 all docs	40 docs citations	40 times ranked	3395 citing authors

#	Article	IF	Citations
1	Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy. JCI Insight, 2022, 7, .	5.0	10
2	HIF activation enhances FcÎ³RIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 131.	8.6	9
3	Abstract 1642: A novel FcÎ³RIIB-blocking antibody to enhance FcÎ³R-dependent antitumor immunity. , 2021, , .		0
4	LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation. JCI Insight, 2020, 5, .	5.0	26
5	Abstract IA03: Optimizing immunostimulatory antibodies for cancer immunotherapy. , 2020, , .		0
6	Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcÎ³R Expression. Cancer Immunology Research, 2019, 7, 1876-1890.	3.4	23
7	New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcÎ³RIIB (CD32B). Journal of Leukocyte Biology, 2018, 103, 1077-1088.	3.3	17
8	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology, 2017, 35, 569-576.	17.5	248
9	Leukocyte Ig-Like receptor B1 restrains dendritic cell function through increased expression of the NF-ÎºB regulator ABIN1/TNIP1. Journal of Leukocyte Biology, 2016, 100, 737-746.	3.3	13
10	Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia, 2016, 30, 2179-2186.	7.2	69
11	B Cells Promote Pancreatic Tumorigenesis. Cancer Discovery, 2016, 6, 230-232.	9.4	49
12	Resistance is futile: Targeting the inhibitory FcÎ³RIIB (CD32B) to maximize immunotherapy. OncoImmunology, 2016, 5, e1069939.	4.6	9
13	Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood, 2015, 125, 1901-1909.	1.4	74
14	Upregulation of FcÎ³RIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood, 2015, 125, 102-110.	1.4	47
15	FcÎ³R requirements leading to successful immunotherapy. Immunological Reviews, 2015, 268, 104-122.	6.0	41
16	Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies. Cancer Cell, 2015, 27, 138-148.	16.8	135
17	Antagonistic Human FcÎ³RIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy InÂVivo. Cancer Cell, 2015, 27, 473-488.	16.8	108
18	Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human FcÎ³ Receptors. Journal of Immunology, 2015, 195, 5503-5516.	0.8	37

#	Article	IF	Citations
19	Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 365-365.	1.4	0
20	Inhibitory FcÎ³RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood, 2014, 123, 669-677.	1.4	60
21	Immunotherapy Targeting Inhibitory FcÎ³ Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization. Journal of Immunology, 2013, 191, 4130-4140.	0.8	29
22	WAPing Out Pathogens and Disease in the Mucosa: Roles for SLPI and Trappin-2. , 2013, , 141-166.		0
23	Rituximab Induced Internalisation of B-Cells CD20 Receptor is Independent of the Inhibitory FC Receptor (CD32B) Intracellular Cell Signalling. Annals of Oncology, 2012, 23, ix70.	1.2	0
24	Development and characterisation of monoclonal antibodies specific for the murine inhibitory <scp>F</scp>cÎ³<scp>RIIB</scp> (<scp>CD</scp>32<scp>B</scp>). European Journal of Immunology, 2012, 42, 2109-2120.	2.9	35
25	B cellsâ€"Masters of the immunoverse. International Journal of Biochemistry and Cell Biology, 2011, 43, 280-285.	2.8	40
26	WAP domain proteins as modulators of mucosal immunity. Biochemical Society Transactions, 2011, 39, 1409-1415.	3.4	49
27	Interaction with FcÎ³RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody. Journal of Immunology, 2011, 187, 1754-1763.	0.8	202
28	Serine and Cysteine Proteases and Their Inhibitors as Antimicrobial Agents and Immune Modulators. , 2011, , 27-50.		4
29	Filament-associated TSGA10 protein is expressed in professional antigen presenting cells and interacts with vimentin. Cellular Immunology, 2010, 265, 120-126.	3.0	9
30	Alternative mRNA splicing creates transcripts encoding soluble proteins from most LILR genes. European Journal of Immunology, 2009, 39, 3195-3206.	2.9	34
31	Neutrophil Elastase (NE) and NE Inhibitors: Canonical and Noncanonical Functions in Lung Chronic Inflammatory Diseases (Cystic Fibrosis and Chronic Obstructive Pulmonary Disease). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 125-144.	1.4	56
32	The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. Blood, 2008, 111, 3090-3096.	1.4	76
33	Neutrophil Elastase (NE) and NE Inhibitors: Canonical and Noncanonical Functions in Lung Chronic Inflammatory Diseases (Cystic Fibrosis and Chronic Obstructive Pulmonary Disease). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, .	1.2	0
34	Human neutrophil elastase inhibitors in innate and adaptive immunity. Biochemical Society Transactions, 2006, 34, 279.	3.4	62
35	SLPI and elafin: one glove, many fingers. Clinical Science, 2006, 110, 21-35.	4.3	246
36	Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1189-1198.	5.6	71

#	Article	IF	Citations
37	The Antimicrobial/Elastase Inhibitor Elafin Regulates Lung Dendritic Cells and Adaptive Immunity. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 634-642.	2.9	44
38	The Antimicrobial Antiproteinase Elafin Binds to Lipopolysaccharide and Modulates Macrophage Responses. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 443-452.	2.9	58